BioCryst Pharmaceuticals traded at $10.84 this Friday July 1st, increasing $0.26 or 2.46 percent since the previous trading session. Looking back, over the last four weeks, BioCryst Pharmaceuticals gained 9.49 percent. Over the last 12 months, its price fell by 34.22 percent. Looking ahead, we forecast BioCryst Pharmaceuticals to be priced at 10.55 by the end of this quarter and at 9.71 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Chugai Pharma 3,529.00 53.00 1.52% -18.52%
Daiichi Sankyo 3,411.00 35.00 1.04% 45.40%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
BioCryst Pharmaceuticals 10.84 0.26 2.46% -34.22%
ChemoCentryx 26.76 1.98 7.99% 103.03%
DBV Technologies 2.39 -0.16 -6.27% -58.00%
Enanta Pharmaceuticals 49.63 2.36 4.99% 12.29%
Gilead Sciences 62.36 0.55 0.89% -10.01%
GlaxoSmithKline 1,802.60 17.00 0.95% 25.84%
Glaxosmithkline 43.75 0.22 0.51% 8.27%
Incyte Corp 77.67 1.70 2.24% -7.07%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Intra Cellular Therapies 55.17 -1.91 -3.35% 30.58%
Karyopharm Therapeutics 4.73 0.22 4.88% -55.00%
Mirati Therapeutics 71.18 4.05 6.03% -57.53%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Novavax 57.15 5.72 11.12% -73.69%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

BioCryst Pharmaceuticals
BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.